EMA news ‘a substantial positive catalyst’ for Cellectar, says Oppenheimer

Oppenheimer notes Cellectar Biosciences (CLRB) announced receipt of feedback from the Scientific Advice Working Party of the European Medicines Agency that a submission of an application for a conditional marketing authorization, similar to the FDA’s conditional approval, in the EU could be acceptable for iopofosine-I131 as a treatment for post-BTKi refractory patients with Waldenstrom macroglobulinemia. This committee does not opine whether safety and efficacy are sufficient for approval itself. The firm sees the news as a substantial positive catalyst that should bolster Cellectar’s efforts to partner the iopofosine-I131 program. Oppenheimer has a Perform rating on the shares.